N-Methyl-N-ethyltryptamine

N-Methyl-N-ethyltryptamine
Names
Preferred IUPAC name
N-Ethyl-2-(1H-indol-3-yl)-N-methylethan-1-amine
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C13H18N2/c1-3-15(2)9-8-11-10-14-13-7-5-4-6-12(11)13/h4-7,10,14H,3,8-9H2,1-2H3 checkY
    Key: MYEGVMLMDWYPOA-UHFFFAOYSA-N checkY
  • InChI=1/C13H18N2/c1-3-15(2)9-8-11-10-14-13-7-5-4-6-12(11)13/h4-7,10,14H,3,8-9H2,1-2H3
    Key: MYEGVMLMDWYPOA-UHFFFAOYAX
  • c1cccc2c1c(c[nH]2)CCN(CC)C
Properties
C13H18N2
Molar mass 202.295 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

N-Methyl-N-ethyltryptamine (MET) is a psychedelic tryptamine. It is closely related to DMT and DET.[1][2] The lysergamide counterpart of MET is ETH-LAD, an analogue of LSD first developed and characterized by Alexander Shulgin.

There is very little information on the human pharmacology or toxicity of MET. The freebase is believed to be active via vaporization at 15 mg.[3]

  1. ^ Schifano, Fabrizio; Orsolini, Laura; Papanti, Duccio; Corkery, John (2016). "NPS: Medical Consequences Associated with Their Intake". Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. Vol. 32. pp. 351–380. doi:10.1007/7854_2016_15. ISBN 978-3-319-52442-9. PMID 27272067.
  2. ^ Halberstadt, Adam L.; Geyer, Mark A. (2016). "Effect of Hallucinogens on Unconditioned Behavior". Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 159–199. doi:10.1007/7854_2016_466. ISBN 978-3-662-55878-2. PMID 28224459.
  3. ^ "That's okay, you're good" MET trip report - The Vaults of Erowid